Overview

Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the concept of the exenatide test for diagnosis of EHH (earlier induction of symptomatic hypoglycemia compared to placebo within 4 hours after injection).
Phase:
N/A
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborator:
Gottfried und Julia Bangerter-Rhyner-Stiftung
Treatments:
Exenatide
Pharmaceutical Solutions